Granted Patent B2

US 12,262,983 · App. 16/968,231 · Granted Apr 1, 2025

Inventors: Jinghua Wang (Mason, OH); Lili He (Mason, OH)

Assignees: University of Cincinnati; Children's Hospital Medical Center

A61B5/055A61B5/0042G01R33/5601

Abstract

Claims (31)

1. A method for detecting blood-tissue barrier breakdown or disruption, the method comprising:

acquiring first image data of a target region of a subject using a magnetic resonance imaging (MRI) apparatus, said MRI apparatus comprising an image reconstruction unit, with a predetermined spatial resolution, wherein the predetermined spatial resolution is less than 3.4 mm 3 for a voxel or 2.3 mm 2 for a pixel;

administrating exogenous or endogenous tracer into the subject;

acquiring at least one image data of the target region using the MRI apparatus with the predetermined spatial resolution after administration of the tracer;

quantitatively differentiating healthy tissue and pathological tissue with blood-tissue barrier breakdown in the target region using the MRI apparatus based on entire or part of the first image data and the at least one image data; and

visualizing or analyzing the blood-tissue barrier breakdown of pathological tissue with the image reconstruction unit based on the differentiation,

wherein the predetermined spatial resolution is determined by at least one fraction of blood-tissue barrier breakdown in a voxel or pixel.

2. The method of claim 1 , wherein administrating the exogenous or endogenous tracer comprises:

administering the exogenous tracer by injection or orally; and

administering the endogenous tracer by labeling or physiological changes.

3. The method of claim 1 , wherein detection sensitivity of the blood-tissue barrier breakdown increases as the predetermined spatial-resolution increases.

4. The method of claim 1 , wherein the predetermined spatial resolution is less than 1 mm 3 for a voxel of the image data or 1 mm 2 for a pixel of the image data.

5. The method of claim 1 , wherein the predetermined spatial resolution is less than 0.5 mm 3 for a voxel of the image data or 0.64 mm 2 for a pixel of the image data.

6. The method of claim 1 , wherein the predetermined spatial resolution is less than 0.35 mm 3 for a voxel of the image data or 0.5 mm 2 for a pixel of the image data.

7. The method of claim 1 , wherein the predetermined spatial resolution is less than 0.13 mm 3 for a voxel of the image data or 0.25 mm 2 for a pixel of the image data.

8. The method of claim 1 , wherein the at least one image data are acquired with at least one of dynamic contrast agent MRI, dynamic susceptibility contrast MRI, contrast enhanced MRI, and nuclear spin labelling MRI.

9. The method of claim 1 , further comprising at least one of detecting a disease lesion, diagnosing a disease, performing treatment plan, monitoring disease therapy, or staging a disease.

10. The method of claim 1 , wherein the detectable blood-tissue barrier breakdown of the pathological tissue is associated with early detection of various diseases, selected from the group consisting of tumor, multiple sclerosis, inflammation disease, infection disease, traumatic nerve injury, Alzheimer disease, Parkinson diseases, stroke, vascular disease, and various psychiatric disorders selected from the group consisting of: schizophrenia, autism spectrum disorder, and mood disorders.

11. The method of claim 1 , further comprising determining a change of blood-tissue barrier permeability induced by drugs or techniques based on analysis of blood-tissue barrier breakdown of pathological tissue.

12. A system for detecting blood-tissue barrier breakdown or disruption, the system comprising:

a receiver configured to acquire image data of a target region of a subject using a magnetic resonance imaging (MRI) apparatus with a predetermined spatial resolution, wherein the predetermined spatial resolution is determined by at least one fraction of blood-tissue barrier breakdown in a voxel or pixel and the predetermined spatial resolution is less than 3.4 mm 3 for a voxel or 2.3 mm 2 for a pixel;

an image reconstruction unit; and

a processor configured to:

receive, from the receiver, first image data of the target region of the subject before an exogenous or endogenous tracer is administered to the subject;

receive, from the receiver, at least one image data of the target region of the subject after the exogenous or endogenous tracer is administered into the subject;

quantitatively differentiate pathological tissue with blood-tissue barrier breakdown from healthy tissue in the target region based on entire or part of the acquired first image data and the acquired at least one image data using the MRI apparatus; and

visualize or analyze the blood-tissue barrier breakdown of the pathological tissue based on the differentiation, using the image reconstruction unit.

13. The system of claim 12 , wherein the predetermined spatial resolution is less than 1 mm 3 for a voxel of the image data or 1 mm 2 for a pixel of the image data.

14. The system of claim 12 , wherein the predetermined spatial resolution is less than 0.5 mm 3 for a voxel of the image data or 0.64 mm 2 for a pixel of the image data.

15. The system of claim 12 , wherein the predetermined spatial resolution is less than 0.35 mm 3 for a voxel of the image data or 0.5 mm 2 for a pixel of the image data.

16. The system of claim 12 , wherein the predetermined spatial resolution is less than 0.13 mm 3 for a voxel of the image data or 0.25 mm 2 for a pixel of the image data.

Assignments (4)

Continuity (2)

References Cited (30)